Prof. Shuhang Wang

Prof. Shuhang Wang is a distinguished oncologist and clinical researcher affiliated with the Chinese Academy of Medical Sciences (CAMS) Cancer Center in Beijing, a leading institution in cancer treatment, research, and education in China. Her dual roles as Associate Chief Physician and Secretary of the Good Clinical Practice (GCP) Center highlight his expertise in both clinical oncology and the oversight of clinical trials.

Dr. Shuhang Wang graduated from Peking University and was Postdoctoral fellow at Mayo Clinic. She is devoted to clinical trials of new antineoplastic drugs and their translational research, including the research and development of cell gene and therapeutic tumor vaccine products, etc.

Dr. Wang is skilled in individualized targeted and immunotherapy for rare tumors and lung cancer, as well as multidisciplinary comprehensive treatment of advanced solid tumors. Focus on the mechanism research of antineoplastic drugs, and the research of tumor heterogeneity and immune microenvironment.

Dr Wang published more than 40 articles as the first author in internationally renowned oncology journals such as Cancer Cell, JAMA Oncology, and Journal of Thoracic Oncology.

Dr Wang has presided over or participated in several projects such as the construction of the clinical trial capacity improvement (GCP) platform, the National Natural Science Foundation of China, and ASCO LIFE.

Roles and Responsibilities

1. Clinical Practice:
   • As an Associate Chief Physician, Prof. Wang specializes in oncology, likely focusing on a specific cancer type (e.g., solid tumors, hematologic malignancies). Her clinical work involves patient care, multidisciplinary treatment planning, and mentorship of junior physicians.
2. GCP Center Leadership:
   • As Secretary of the GCP Center, she plays a pivotal role in ensuring compliance with international and national clinical trial standards (ICH-GCP). His responsibilities include:
     • Overseeing the design, approval, and execution of cancer-related clinical trials.
     • Facilitating collaborations between researchers, pharmaceutical companies, and regulatory bodies.
     • Ensuring ethical conduct and data integrity in trials.
3. Research Focus:
   • Prof. Wang is likely involved in translational and clinical cancer research, particularly in drug development, targeted therapies, and immunotherapy.
   • Her work may contribute to China’s national cancer research initiatives under CAMS and the National Cancer Center (NCC).

Affiliations and Collaborations

• Chinese Academy of Medical Sciences (CAMS): A premier medical research organization under China’s National Health Commission.
• National Cancer Center (NCC): CAMS Cancer Center serves as the NCC, aligning Prof. Wang’s work with national cancer control strategies.
• Potential ties to Peking Union Medical College (PUMC), given CAMS’s close academic partnership with PUMC.

Education and Training

• Medical degree and specialization in oncology, likely from a top-tier Chinese institution (e.g., Peking Union Medical College).
• Additional training in clinical trial management (GCP certification) and possibly international research collaborations.

Contributions to Oncology

• Clinical Trials: Leadership in Phase I–IV trials for novel anticancer therapies.
• Publications: Likely authored or co-authored research papers in peer-reviewed journals (specific publications would require further verification).
• Policy and Guidelines: Potential involvement in drafting national guidelines for cancer treatment or clinical trial conduct.

Professional Recognition

• May hold memberships in organizations like the Chinese Society of Clinical Oncology (CSCO) or Chinese Anti-Cancer Association (CACA).
• Possible participation in international oncology consortia (e.g., ASCO, ESMO).

Contact Information

• Institution: Cancer Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing.
• Address: Likely based at the CAMS Cancer Hospital in Panjiayuan, Chaoyang District, Beijing.

Prof. Shuhang Wang is an accomplished oncologist, clinical researcher, and clinical trial specialist affiliated with the Chinese Academy of Medical Sciences (CAMS) Cancer Center in Beijing, one of China’s most prestigious cancer treatment and research institutions.

Her dual roles as Associate Chief Physician and GCP (Good Clinical Practice) Center Secretary highlight his expertise in both clinical oncology and the management of cutting-edge cancer trials. Below is a detailed breakdown of his specialty and contributions to the field.

1. Clinical Oncology Specialty

Prof. Wang’s clinical work likely focuses on medical oncology, with a subspecialty in one or more of the following areas:

A. Solid Tumor Oncology

• Lung Cancer: Given China’s high incidence of lung cancer, he may specialize in targeted therapies, immunotherapy (PD-1/PD-L1 inhibitors), and precision medicine for NSCLC and SCLC.
• Gastrointestinal Cancers: Expertise in colorectal, gastric, and liver cancers, possibly with a focus on molecular profiling and personalized treatment.
• Breast Cancer: Involvement in hormone receptor-positive, HER2+, and triple-negative breast cancer (TNBC) clinical trials.

B. Hematologic Malignancies (Possible Involvement)

• If his work extends to blood cancers, he may contribute to leukemia, lymphoma, and myeloma research, particularly in CAR-T cell therapy and novel biologics.

C. Multidisciplinary Tumor Boards

• As a senior oncologist, he likely participates in tumor board discussions, integrating surgery, radiation, and systemic therapy for optimal patient outcomes.

2. Clinical Trials & Drug Development (GCP Leadership)

As Secretary of the GCP Center, Prof. Wang plays a pivotal role in designing, approving, and supervising cancer clinical trials, ensuring compliance with international (ICH-GCP) and Chinese regulatory standards.

Key Areas of Trial Expertise:

• Phase I-III Trials: Early-phase dose-finding studies and large-scale randomized trials for new targeted drugs, immunotherapies, and combination therapies.
• First-in-Human Studies: Overseeing innovative therapies (e.g., bispecific antibodies, ADC drugs) in China.
• Collaborations with Pharma & Biotech: Partnering with domestic (Hengrui, BeiGene) and multinational (Roche, Merck) companies to bring novel treatments to patients.
• Real-World Evidence (RWE) Studies: Contributing to post-marketing surveillance of approved cancer drugs in the Chinese population.

3. Research & Academic Contributions

Prof. Wang is likely involved in translational research, bridging lab discoveries with clinical applications.

Potential Research Focus Areas:

• Biomarker Discovery: Identifying predictive biomarkers for immunotherapy response.
• Resistance Mechanisms: Studying why cancers develop resistance to TKIs, PARP inhibitors, or checkpoint inhibitors.
• Chinese Cancer Genomics: Contributing to large-scale genomic projects (e.g., pan-cancer studies in Asian populations).

Publications & Conference Participation

• Likely an author of peer-reviewed papers in journals like Lancet Oncology, Journal of Clinical Oncology (JCO), or Chinese Medical Journal.
• Speaker or panelist at CSCO (Chinese Society of Clinical Oncology), ASCO, or ESMO Asia conferences.

4. Leadership in National Cancer Policy

Given his position at CAMS (a National Cancer Center-affiliated institution), he may contribute to:

• National Cancer Guidelines: Helping draft standardized treatment protocols for China.
• Regulatory Advisory Roles: Advising the NMPA (China’s FDA) on oncology drug approvals.

5. Teaching & Mentorship

• Likely supervises medical students, residents, and fellows from Peking Union Medical College (PUMC).
• May lead GCP training workshops for investigators and clinical trial staff.

Since Dr. Shuhang Wang (王书航) is primarily known for his role as an Associate Chief Physician and GCP Center Secretary at the Chinese Academy of Medical Sciences (CAMS) Cancer Center, his work focuses more on clinical research, trial oversight, and systemic cancer therapies rather than surgical or interventional procedures.

1. Systemic Cancer Therapies (Medical Oncology)

• Targeted Therapies
  • EGFR/ALK/ROS1 inhibitors (e.g., Osimertinib, Crizotinib) for lung cancer
  • HER2-targeted drugs (e.g., Trastuzumab, Pyrotinib) for breast & gastric cancers
  • VEGF inhibitors (e.g., Apatinib, Bevacizumab) for colorectal & liver cancers
  • PARP inhibitors (e.g., Olaparib) for BRCA-mutated cancers
• Immunotherapies
  • PD-1/PD-L1 inhibitors (e.g., Sintilimab, Camrelizumab, Pembrolizumab)
  • Combination therapies (e.g., chemo + immunotherapy for NSCLC)
  • Investigational immune checkpoint inhibitors (early-phase trials)
• Chemotherapy & Adjuvant Therapy
  • Platinum-based regimens for lung, gastric, and esophageal cancers
  • Capecitabine/Tegafur for GI cancers
  • Neoadjuvant/adjuvant therapy for breast cancer

2. Clinical Trials & Novel Therapeutics (GCP Center Leadership)

• Phase I-III trials for:
  • Next-gen TKIs (Tyrosine Kinase Inhibitors)
  • Antibody-Drug Conjugates (ADCs) (e.g., RC48, DS-8201)
  • CAR-T/CAR-NK cell therapies (for hematologic & solid tumors)
  • Bispecific antibodies (e.g., PD-1/CTLA-4 dual-targeting drugs)
  • Cancer vaccines (mRNA-based or peptide vaccines)
• First-in-human (FIH) trials for innovative molecules developed in China.

3. Precision Medicine & Molecular Profiling

• NGS (Next-Generation Sequencing) for tumor mutation analysis
• Liquid biopsy applications in monitoring treatment resistance
• Patient-derived xenograft (PDX) models for personalized therapy testing

4. Supportive & Palliative Care

• Management of treatment-related side effects (e.g., immunotherapy-induced pneumonitis)
• Pain management in advanced cancer